Nevakar Injectables’ business model focuses on repositioning and repurposing existing drugs to address unmet needs that are patient and health care system centric. Nevakar Injectables’ unique ideation and pipeline development process allows us to accelerate discovery, development and commercial launch.
We call this novel approach NuPharmingTM.
portfolio
Hospital Injectables
Hospital Injectables is an underserved market presenting significant patient and healthcare system value. Suboptimal products and delivery are key unmet needs in this market.
Our Pipeline
Novel Injectables
Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
NVK009Acute Pain |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NVK006Anti-infective |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NVK043Novel Injectable |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
Critical Care Injectables
Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
NVK014Cardiovascular | Approved | ||||
NVK004Cardiovascular |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NVK003Anesthesia |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NVK005Oncology |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NVK019Cardiovascular |
Research
|
Preclinical
|
Phase I
|
Phase II
|
Phase III
|

References for Hospital Injectables:
5. https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html. 6. Gan TJ et al. Curr Med Res Opin. 2014;30(1):149-160 7.https://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/ 8. https://www.sccm.org/Communications/Critical-Care-Statistics.